iShares 0 3 Month Treasury Bond ETF vs 10X Genomics Inc — how do they compare? iShares 0 3 Month Treasury Bond ETF trades at $100.7, while 10X Genomics Inc trades at $47.48 (market cap $5.48B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| SGOV | TXG | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $100.74 | $45.80 |
52-Week Low | $100.28 | $11.34 |
Market Cap | — | $5.48B |
Enterprise Value | — | $5.02B |
Signals from Pluang's Aura AI — not financial advice
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.59 with minimal daily movement, reflecting its stable nature as a short-term Treasury vehicle. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. The ETF continues to attract institutional interest as investors seek yield and stability amid rate uncertainty, with recent articles highlighting its role in cash management strategies.
SGOV offers investors a low-risk cash alternative with competitive yields around 3.5-3.6%, though its performance remains highly sensitive to Federal Reserve policy decisions. The primary risk involves potential rate hikes that could pressure short-term bond values, while the opportunity lies in providing liquidity and income in volatile markets.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Trailing returns across standard periods
Latest headlines on both assets
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →